Product Overview
[Drug Name]
Generic Name: Olsalazine Sodium Capsules
Trade Name: GengXian Olsalazine Sodium Capsules 0.25g*24 Capsules
Pinyin Code: GengXian AoShaLaQinNaJiaoNang 0.25g*24Li
[Main Ingredients]
The main ingredient of this product is olsalazine sodium.
[Properties]
This product consists of dark yellow granules and powder.
[Indications/Main Functions]
For the treatment of mild to moderate acute and chronic ulcerative colitis.
[Specifications]
0.25g*24 Capsules (GengXian)
[Dosage and Administration]
Oral: Start with 1g (4 capsules) daily, divided into 2 doses. Gradually increase the dose, increasing to 3g (12 capsules) daily, divided into 3-4 doses, if necessary. For maintenance treatment, take 0.5g (2 capsules) twice daily. This product should be taken with meals.
[Adverse Reactions]
The most common adverse reaction is diarrhea, which is usually transient and occurs at the start of treatment or when the dose is increased. Diarrhea can be controlled by reducing the dose or taking this drug with food. Other adverse reactions include nausea, vomiting, upper abdominal discomfort, indigestion, abdominal pain, rash, headache, dizziness, insomnia, arthralgia, leukopenia, and transient anxiety.
[Contraindications]
This drug is contraindicated in patients with salicylic acid allergy or severe hepatic or renal impairment.
[Drug Interactions]
This drug may increase the prothrombin time when taken with warfarin.
[Precautions]
1. Use with caution in patients with intestinal reactions. 2. If a dose is missed, take it immediately, but do not take two doses at the same time.
[Pediatric Use]
The recommended pediatric dose is 20-40 mg/kg per day. The maintenance dose is 15-30 mg/kg per day, or as directed by a physician.
[Use in Elderly Patients]
The current information is unknown.
[Overdose]
The current information is unknown.
[Pharmacology and Toxicology]
This product consists of two molecules of 5-aminosalicylic acid linked by an azo bond. 5-aminosalicylic acid is an active ingredient in the treatment of ulcerative colitis. However, after oral administration, 5-aminosalicylic acid is absorbed in the small intestine and excreted in the urine after acetylation, preventing it from reaching the colon. This product is neither absorbed nor decomposed in the stomach and small intestine. Once in the colon, the azo bond is broken down by bacteria, breaking down into two molecules of 5-aminosalicylic acid. These molecules act on the inflamed colonic mucosa, inhibiting prostaglandin synthesis and the formation of inflammatory mediators such as leukotrienes, reducing intestinal cell membrane permeability, and alleviating intestinal mucosal edema.
